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Abstract
Studies directed at establishing the structural features that control Pt/DNA interactions and
the anticancer activity of Pt drugs are described. [H,N]-HSQC 2D NMR spectroscopic
studies of the reactions of cisplatin with oligonucleotides containing ApG and GpA binding
sites reveal dramatic differences in the rates of formation of monofunctional adducts at the
two sites. When the reactant is cis-[Pt(NH)(OH)]* no such differences are observed
suggesting that outer-sphere interactions between the reactant and the oligonucleotide may
play a substantial role in determining the rates. Rates of closure to the bifunctional adducts
are similar to those observed for cisplatin. Studies of the adduct profiles formed by sterically
bulky and/or optically active complexes reveal that steric interactions play a major role in
mediating the binding of Pt(ll) to DNA but that hydrogen bonds play less of a role. In vitro
cytotoxic activities for these complexes do not always follow the trends that would be
expected on the basis of the adduct profiles.
1. Introduction
Although it has been widely accepted that the binding of Pt(ll) to DNA is ultimately
responsible for the anticancer activity of Pt based anticancer drugs [1-4], the factors that
control the DNA binding and how these influence the anticancer activity are poorly
understood [5]. For example, molecular models and some crystal structures reveal hydrogen
bonds between the oxygen atoms of DNA and the amine ligands that remain bound to Pt [6-
13]. On the basis of these observations it has been proposed that the ability to form such
hydrogen bonds is required for DNA binding and anticancer activity [9,14]. This suggestion is
consistent with the observation that replacement of all H atoms on the amine groups with
alkyl groups greatly diminishes the anticancer activity [15] but is not consistent with the
increasing number of compounds that are active but do not have H(amine) atoms. An
alternative explanation is that it is the small size of the H(amine) atoms rather than their
hydrogen bonding ability that is important [5,16] but the role of steric factors in mediating
Pt/DNA interactions has received relatively little attention.
To date, most studies of Pt/DNA interactions have focused on the final products but to gain
an understanding of what controls the product distribution each step needs to be examined.
The overwhelmingly preferred binding sites are the GpG and ApG sequences [17-21] and
there are indications that sequences with more than two guanine bases are favoured [22,23].
Binding to isolated guanine bases is inherently preferred over binding to isolated adenine
bases [24] but outer-sphere complex formation prior to binding also has the potential to
influence the final product distribution. If this is the case then the bases flanking a binding
site could control binding and ultimately determine the effectiveness of the drug in terms of
its ability to bind to a particular sequence and produce an anticancer effect.
In the present paper we summarise the results of our recent studies of the factors that control
Pt/DNA interactions. In particular we have investigated the reasons for the preference of
drugs such as cisplatin (cis-diamminedichloroplatinum(ll), cis-[Pt(NH)Cl]) to bind to GpG
and ApG sequences and their failure to bind bifunctionally to GpA sequences of DNA. We
have also addressed the roles of hydrogen bonding and steric interactions in influencing the
197VoL 5, No. 4, 1998 Steric Determinants ofPT/DNA Interactions and Anticancer Activity
binding of Pt complexes to DNA and influencing the anticancer activity of these complexes.
2. Results and Discussion
2.1 Kinetic Studies of Pt Binding to GpG, ApG and GpA Sequences
The binding of even simple complexes such as cisplatin to bispurine sequences of DNA (GpG,
ApG or GpA) is a highly complicated process. Hydrolysis of one of the chloro ligands is followed
by formation of one or two monofunctional adducts and each of these will then close at
different rates to produce the bifunctional rates. Thus, a minimum of five species can be
anticipated, as shown in Scheme 1 for the reaction at an ApG site, and following the
appearance and disappearance of these species is difficult. Chottard and colleagues have
successfully used HPLC techniques to quantify trapped intermediates in the reaction between
cis-[Pt(NHz)(OH)]+ and a variety of oligonucleotides containing the GpG sequence [25,26].
They found little selectivity for either the 5’-G or the 3’-G in the formation of the monofunctional
adducts but found substantially more rapid closure to the bifunctional adduct from the 3’-G
monofunctional. Sadler, Berners-Price and colleagues have obtained similar results using
[H,N]-HSQC 2D NMR spectroscopy [27]. They also studied the reaction of cisplatin with
oligonucleotides and found a higher rate of binding to the 3’ guanine of a GpG pair and faster
closure to the bifunctional adduct from this base [28,29].
(1) ,NH3
H2OI KH 5’ KS’
....C,I +
H3N,----,OH2 (5)
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(6)
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Scheme
We have used [H,N]-HSQC 2D NMR spectroscopy to follow the rates Of binding of cisplatin
and cis-[Pt(NH3)2(OH2)2]2* to the self-complementary sequences d(5-AATTAGTACTAATT-3)
and d(5-AATTGATATCAATT-3) containing ApG and GpA sites respectively [30]. A typical
spectrum showing starting materials, intermediates and the final product for reaction at the
ApG site is shown in Figure 1 and a plot showing the appearance and disappearance of each
of these species is shown in Figure 2. Similar plots were obtained for the reaction at the GpA
site. Rate constants for each step were extracted from numerically optimised fits to these data
curves and the calculated curves are also shown in Figure 2. Calculated rate constants are
listed in Table along with those reported previously for reaction at the GpG site [28,29].
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Figure 1. [H,N]-HSQC 2D NMR spectrum from the reaction
between cisplatin and the oligonucleotide d(5-
AATTAGTACTAATT-3) taken from reference 30. Numbered
species are defined in Scheme 1.
Rates of monofunctional adduct formation at the ApG site are broadly similar to those at the
GpG site. Binding at the 3’-G is more rapid than binding to the 3’-G of the GpG sequence
and binding at the 5’-A is remarkably similar in rate to binding at the 5’-G of GpG. In contrast
rates of monofunctional binding to GpA site are markedly slower. Thus, binding at the 3’-A is
two orders of magnitude slower than binding to the 3’-G’s of GpG and ApG and binding at the
5’-G is nearly an order of magnitude slower than is binding to the 3’-bases of GpG and ApG.
Some tentative conclusions can be drawn from these results; (i) the normal preference for
binding to guanine over adenine can be substantially affected by both flanking sequences
and the DNA structure, (ii) the base on the 3’ side of a binding site exerts a substantially
greater influence on the rate of binding than does the base on the 5’ side and (iii) the rates of
monofunctional adduct formation are an important determinant of the final adduct profile.
Rates of closure to the bifunctional adduct are remarkably similar for all three sequences and
follow the same trends. Thus closure from the 3’ side is faster, ranging from 1.6 to 3.2 x 10- s , than closure from the 5’ side that ranges from 0.18 to 0.24 x 10-
s-. The constancy of
these rates is despite the fact that the bases are guanine in some cases and adenine in
others providing further evidence that the DNA structure can overrule the inherent preference
for binding to guanine over adenine. They also show that the major reason for the non-
formation of the bifunctional GpA adduct is the slow rate of formation of the monofunctional
adduct, though this is further exacerbated by the fact that the more rapidly formed
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monofunctional adduct at the GpA sequence is the one that closes more slowly to the
bifunctional adduct.
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Figure 2. Reaction profile for the reaction between cisplatin and
the oligonucleotide d(5-AATTAGTACTAATT-3) taken from
reference 30.
Table 1. Rate constants for the reactions between cisplatin and oligonucleotides
Rate Constant
K, (10-
s-)
K3 (M-
s4)
K (M-
s-)
K3o (10.5 s-)
Kc (10-
s-)
AG3o
1.71(0.03)
0.96(0.07)
0.14(0.02)
1.59(0.05)
0.18(0.07)
GA3O
1.13(0.02)
0.005(0.00)
0.023(0.002)
2.1(0.5)
0.20(0.02)
GG28
1.83(0.03)
0.47(0.04)
0.15(0.03)
3.2(0.1)
0.24(0.18)
Table 2. Rate Constants for the Reactions Between cis-[Pt(NH3)2(OH2)2]
2/ and DNA
Rate Constant
K3 (M-
s-)
K (M-
s-)
K3o (10.5 s-)
Kc (10-
s-
AG3O
0.419(0.009)
not observed
3.71(0.05)
not observed
GA3O
not observed
0.500(0.007)
not observed
0.162(0.005)
GG27
too fast to measure
too fast to measure
25(3)
4.9(0.4)
Rates of the reactions of cis-[Pt(NH3)(OH2)2]
2/ at the same three sequences (Table 2) are
different in many respects to those for cisplatin. Only G monofunctional adducts are
observed in the reactions of cis-[Pt(NH3)2(OH2)]
2/ at both the ApG and GpA sites and these
form at similar rates. Thus, the rate of binding at GpA in particular is strongly influenced by
the nature of the incoming reactant consistent with outer-sphere complex formation having a
strong influence on the reaction rate and possibly on sequence selectivity. The rates of
closure to the bifunctional adducts are similar to those observed for cisplatin and because
the 5’-G monofunctional adduct formed at the GpA site is the one that is slow to close, the
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overall rate of formation of the GpA bifunctional adduct is much slower than formation of the
ApG or GpG adducts. Curiously, the rates of closure were approximately an order of
magnitude faster at the GpG sequence and the rates of monofunctional adduct formation
were too rapid to measure.
2.2 Stereoselective Interactions Between Pt and DNA
The relative importance of interstrand and intrastrand bifunctional adducts remains an
open question and we have previously described the design of a series of compounds to
probe this question [31-33].
H
-HIN/H
t
Nxl-t
Intrastrand GpG crosslink
Scheme II
Interstrand GG crosslink
The design was based on the differences in the orientations of the hydrogen bonds formed in
each type of adduct and therefore the compounds were also potential probes of the
importance of these hydrogen bonds. In the interstrand adduct the hydrogen bonds lie
approximately in the coordination plane while in the intrastrand adduct they are
approximately perpendicular to the coordination plane as shown in Scheme II.
Thus, compounds that are only able to form hydrogen bonds close to the coordination plane
are expected to be more suited to forming interstrand adducts. The complex [PtCl(hpip)]
(hpip = 1,4-diazacycloheptane, Scheme III) was the first selected on this basis and we were
able to show that it formed interstrand adducts as readily as cisplatin and also that its ability
to form intrastrand GpG adducts was substantially diminished compared to that of cisplatin
[34]. Taken with the unusually low in vitro cytotoxicity of [PtCl(hpip)], these results may
indicate that the interstrand adducts do not contribute significantly to the anti-cancer activity
of Pt(ll) based anticancer drugs [34]. This is a question that needs further investigation and
we are currently preparing and testing compounds related to [PtCl(hpip)].
HNPt’NH
Scheme III
When measuring the intrastrand adducts formed by [PtCl(hpip)] on DNA two GpG adducts in
substantially different proportions are observed [34]. The same two peaks are observed in the
reaction of [PtCl(hpip)] with isolated GpG, this time in equal proportions [35]. 1D and 2D
NMR spectra of these two peaks showed them to be isomers of the expected [Pt(GpG)(hpip)]
complex [35]. Two isomers are expected because of the asymmetry of the hpip and GpG
ligands. Close contacts between the H8 atoms of the GpG and protons on either the
ethylene or propylene links on the backbone of the hpip ligands were evident in the NOESY
spectra and these allowed us to identify the isomers [35]. Peak corresponds to the isomer in
which the propylene link is adjacent to the floor of the major groove of the DNA and ieak II
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to the isomer in which the ethylene link adopts this position. Molecular mechanics models of
each of these isomers on a DNA fragment show substantial differences in the severity of the
steric clashes between the linking groups and the DNA [36]. Thus, in isomer close contacts
occur between in the propylene link and the DNA. These produce substantial distorti,ons in
the coordination geometry about the Pt and contacts as short as 2.55 remain in the
energy-minimised models. In isomer II the contacts are significantly longer (>2.72 =) and the
distortion in the coordination sphere less. These observations are in accord with the
proportions of each isomer that are observed with isomer only accounting for 7% of the Pt
bound to the DNA and isomer II accounting for 25%. The amount of isomer II formed is
close to that expected on the basis of the results for cisplatin, assuming that the ability to
form two isomers leads to a 50% reduction in the amount of each expected. Thus, these
results are all consistent with steric interactions between the amine ligand and the DNA
having a significant influence on the interactions with the DNA and on the final adduct
profile. In neither isomer are hydrogen bonds observed between the H(amine) atoms and the
DNA but, as mentioned, the amount of isomer II formed is not greatly diminished compared to cisplatin. Thus, the ability to form these hydrogen bonds does not appear to be a major
mediator of Pt/DNA interactions in this case.
2.3 Enantioselective Complexes as Probes of the Roles of Steric and Hydrogen Bonding
Interactions
In order to further test the importance of hydrogen bonds between the amines and DNA in
mediating the formation of GpG intrastrand adducts we designed and prepared a series of
complexes of chiral diamine ligands. The design principle is shown in Scheme IV and is
based on the orientation of the hydrogen bonds and the chirality of the GpG adduct.
Enantiomer A has two amine protons disposed appropriately for the formation of the
hydrogen bonds while enantiomer B has alkyl groups disposed toward the hydrogen bond
acceptors. If these hydrogen bonds are important then enantiomer A should be readily able
to form the GpG adduct and enantiomer B less so. Additionally, if the GpG adduct is
primarily responsible for the anticancer activity of such complexes then enantiomer A
should be substantially more active than enantiomer B.
EnantiomerA
Scheme IV
Enantiomer B
Obtaining compounds that meet these design goals has proven difficult. Chirality at the
amine groups is unstable and therefore ligands with inert chiral centres adjacent to the
amine were chosen in the expectation that they would impose the required chirality via
atropisomerism. Our first target compounds, [PtCl(2,4-pentanediamine)] and [PtCI(N,N’-
dimethyl-l,2-cyclohexanediamine)], did not meet these requirements because two
diastereomers were observed in each case [31]. However, variants of the ahaz ligand (ahaz =
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3-aminohexahydroazepine, Scheme V), were successful in that the undesired diastereomer
accounted for less than 5% of the complexes [33]. The endocyclic nature of one of the
amine groups means the chirality at that centre is rigorously imposed and an alkyl group on
the exocyclic amine adopts the orientation that gives rise to the required trans hydrogen
atoms more than 95% of the time.
Cl.,,,il__,l,,,.Cl
H
/
Scheme V
In the first phase of this study we studied the enantiomers of the parent complex [PtCl(ahaz)].
As with [PtCl(hpip)], the inequivalence of the amine groups of the ahaz ligand means that
two GpG adducts are observed for each enantiomer as shown in Scheme VI. The amounts of
each of these formed, measured by enzymatic digestion and HPLC separation, are also
shown in Scheme VI.
For the R-enantiomer the two isomers are observed in approximately equal amounts but for
the S-enantiomer the amounts differ substantially, one being similar to the R enantiomer and
the other more that three times as abundant. Using 2D-NMR spectroscopy were have
established that the most abundant adduct is the one in which the exocyclic NH group of
the S-enantiomer is oriented toward the 5’ side of the adduct (S(a) in Scheme VI). Molecular
mechanics models of the four isomers provided a possible explanation for these observations
because for R(a), R(b) and S(b) substantial steric clashes are observed between the ligands
and the DNA but for S(a) the entire ligand lies in the major groove and makes no close
contacts with the DNA. Thus, these results provide further support for the notion that steric
clashes between the complex and DNA can exert a significant influence on the adduct
profile. They also provide evidence that the ability to form hydrogen bonds may not be as
important because for each of the R isomers only one of the hydrogen bonds is able to form
whereas for each of the S isomers both hydrogen bonds can form but the amounts of each
isomer formed do not correlate with the number of hydrogen bonds that can form.
The S-enantiomer forms substantially more bifunctional GpG adducts (37%) than does the R-
enantiomer (21%). Thus, if this adduct was responsible for effecting the anti-cancer activity,
then the S-enantiomer would be expected to be more active. We have measured the activity
of the both enantiomers against a number of cell lines and the results are given in Table II1.
In nearly all cases the two enantiomers have similar activities and in some cases the R-
enantiomer appears to be the more active, in contrast to the expectations outlined above.
Other factors such as cellular uptake could contribute to these results but we have shown that
there is no enantioselective difference in the uptake [32]. Alternatively, it has been
suggested that anti-cancer activity depends on the ability of proteins to recognise adducts
and initiate events that lead to cell death [37]. It may be that the additional steric
interactions observed for the R-enantiomer lead to additional bending of the DNA that in turn
lead to better recognition.
In vitro cytotoxicities of complexes of the substituted ahaz complexes (Scheme VII) are
given in Table IV [33]. Addition of a methyl or ethyl group to the exocyclic amine results
in a nearly five-fold drop in the activity of the complexes. This is in contradiction to the
structure-activity rule that high activity is usually observed when each amine group has
one or more hydrogen atoms. When two methyl groups are added to the exocyclic
nitrogen the activity does not change significantly compared to the value for a single
added methyl group. Again, this is unexpected because structure-activity rules suggest
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that removal of both hydrogen atoms from one of the amine groups should lead to a
substantial drop in the cytotoxicity
(a) 9 or 12%
R-ahaz
(b) 12 or9%
Ca) 30% (b) 7%
S-ahaz
Scheme Vl
Table 3. Cytotoxicity (ICo) values (M) determined in human bladder tumour cell lines.
Numbers in parentheses are standard errors in units of the last significant figure quoted.
platinum complexes
MTT assay
cisplatin
[Pt(R-ahaz)Cl]
[Pt(S-ahaz)Cl]
SRB assay
cisplatin
[Pt(R-ahaz)Cl]
[Pt(S-ahaz)Cl]
UCRU BL13/0
1.9(5)
1.3(2)
2.0(2)
9.5(18)
7.2(4)
12.3(7)
PC9
1.4(2)
5.9(1)
3.0(4)
5.0(5)
11.o(15)
11.7(9)
ICso (#M)
PC9cisR
11.7(31)
16.0(10)
15.5(13)
>17.5
27.3(35)
25.0(15)
DU145
1.8(8)
2.9(1)
3.4(3)
1.0(2)
3.3(2)
3.7(3)
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[PtC12(meahaz)] [PtC12(etahaz)]
Scheme VII
[PtC12(dimeahaz)]
In all of these complexes and against most cell lines the R-enantiomer is significantly
more active than the S. Thus, it is clear from the foregoing studies that much remains to
be established about what controls Pt/DNA interactions and how these in turn relate to
anti-cancer activity.
Table 4. IC50 values.
Drug
cisplatin
[Pt(R-ahaz)CI2]
[Pt(S-ahaz)CI2]
[Pt(R-meahaz)CI2]
[Pt(S-meahaz)CI2]
[Pt(R-etahaz)CI2]
[Pt(S-etahaz)C 12]
[Pt(R-dimeahaz)CI2]
[Pt(S-dimeahaz)CI2]
BL1310
mean
1.9(0.5)
I. 3(0.2)
2.0(0.2)
7.3(1.3)
11.7(1.6)
7.4(1.1)
19(2.1)
7.7(2.1)
10.2(1.4)
PC9
mean
1.4(0.2)
5.9(0.1)
3.0(0.1)
13.3(1.9)
13.7(1.2)
20(3.5)
31(4)
13.5(3.4)
11.8(2.6)
PC9-cisR
mean
11.7(3.1)
16.0(1.0)
15.3(1.3)
19.0(1.2)
38.3(8.0)
44(4.4)
79.7 (8.5)
29.3(1.5)
28.7(2.2)
DU145
mean
1.8(0.8)
2.9(0.1)
3.4(0.3)
6.7(1.3)
10.1(1.7)
9.5(0.9)
21.3(2.4)
7.3(0.2)
11.5(0.8)
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